SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

Spruce Biosciences is trending following FDA breakthrough therapy designation for its tralesinidase alfa in treating Sanfilippo Syndrome Type B, sparking community enthusiasm. Some investors believe the stock is being manipulated to suppress the price, while others anticipate significant gains due to its small float and potential for a large move. The focus remains on the broader context of Spruce's pipeline and upcoming catalysts.

Cheniere Energy, Inc. engages in liquefied natural gas (LNG) related businesses. It owns and operates LNG terminals, develops, constructs, and operates liquefaction projects near Corpus Christi, Texas, and at the Sabine Pass LNG terminal. The company was founded by Charif Souki in 1996 and is headquartered in Houston, TX.

Cheniere Energy Inc.

Cheniere Energy is trending due to rising natural gas futures and anticipation of increased demand as winter approaches, sparking discussions around potential upside. Community members are actively analyzing LNG's energy export focus, accumulation patterns, and global demand in the context of multi-year resistance tests. Options activity and actionable alerts further contribute to the heightened interest in $LNG.

Invesco DB US Dollar Index Trust - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

UUP is trending amid discussions around dollar strength and potential Federal Reserve actions. Community members are analyzing technical patterns and considering the fund's positioning relative to other assets like gold and equities. Factors such as economic data releases and central bank policies are expected to influence the dollar's trajectory.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altria is trending as call options activity surges, suggesting potential bullish sentiment, while some analysts weigh in on whether it is a value trap. Community discussions also focus on Altria's strategic partnerships in the smoke-free sector and its ongoing competition with Philip Morris, as well as its high dividend yield.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is trending as investors discuss its high dividend yield and monthly payouts, with many sharing their strategies for reinvesting dividends and accumulating shares. The community is also actively speculating on the upcoming dividend announcement, guessing the potential payout amount. Some express concern about the ETF's price performance relative to the broader Nasdaq market.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is trending as investors weigh its dividend yield against recent market volatility and sector rotations. Community discussions involve comparing SCHD to growth-oriented ETFs and income alternatives, with some expressing frustration over short-term performance while others emphasize its long-term value as a stable dividend play. The ETF's composition, particularly its energy sector exposure, is also a point of discussion amid fluctuating oil prices and broader economic concerns.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals is trending due to positive Phase 3 results for zilganersen in treating Alexander disease, a rare neurological disorder, potentially leading to an FDA filing. The community is discussing the drug's breakthrough potential and the company's pipeline, as well as analyst upgrades and price target increases. With unusual options activity and high call volume, there's increased interest in IONS's biopharmaceutical focus and event-driven opportunities.

Rydex Investments - Invesco CurrencyShares Japanese Yen Trust

Invesco CurrencyShares Japanese Yen Trust

The Japanese Yen is trending due to a complex interplay of factors, including Bank of Japan (BoJ) policy speculation and fluctuating USD strength. Community discussions revolve around potential rate hikes, trade dynamics, and the Yen's safe-haven status amid global economic uncertainty. Traders are monitoring key levels and economic data releases for signals on the Yen's future direction within the broader currency market.

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc - ADR

AstraZeneca PLC

AstraZeneca ($AZN) is trending due to a mix of clinical trial updates and strategic moves, including positive data in breast cancer and a significant investment in R&D in Beijing.  The community is focused on the potential impact of these developments on AstraZeneca's growth and competitive positioning, while also monitoring tariff-related pressures.  Discussions also highlight the appeal of partnerships with smaller biotechs in the space.

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Hologic, Inc.

Hologic ($HOLX) is trending following FDA clearance and CE mark for its rapid molecular GI assays on the Panther Fusion platform, which is expected to boost the company's Diagnostics division. Community members are actively discussing the potential growth in women's health diagnostics and the stock's attractive valuation compared to industry peers, with some highlighting unusual options activity and potential takeover interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$OBMP  I&#39;ve been trying to buy this stock all week but my order won&#39;t fill.

Sbizzle

StockTwits For Android 

Nickjames

StockTwits Web

OncBioMune Pharmaceuticals Inc

  I've been trying to buy this stock all week but my order won't fill.

Claudia

@Pyctjh It&#39;s unsolicited quote only, you have to call your broker directly if you want to buy. 

That company market cap has been inflated severly by the issuance of 5B shares from the conversion of the Series D1 Preferred shares in June 2020, after the acquisition of &quot;Avant&quot; .

https://www.otcmarkets.com/filing/html?id=15247906&amp;guid=4Ohwke2PQFqo7bh

They mentioned Avant being in commercial stage, but the revenue for June 2021 is very low compare to current market cap (280k$ vs 4.33B$ market cap!)

Avant is a commercial-stage precision medicine and molecular data-generating company that focuses on the development and commercialization of a series of patented, proprietary data-generating assays that may provide important actionable information for physicians and patients, as well as biopharmaceutical companies, in the areas of oncology.

That&#39;s their website, the one on OTCmarkets isn&#39;t correct.

https://theralink.com/

Otcmarkets

THERALINK ENABLES CLEAR DECISION MAKING FOR AN INDIVIDUAL PATIENT`S CANCER TREATMENT USING PREDICTIVE PROTEIN BIOMARKERS

Theralink

 It's unsolicited quote only, you have to call your broker directly if you want to buy. 

That company market cap has been inflated severly by the issuance of 5B shares from the conversion of the Series D1 Preferred shares in June 2020, after the acquisition of "Avant" .





They mentioned Avant being in commercial stage, but the revenue for June 2021 is very low compare to current market cap (280k$ vs 4.33B$ market cap!)

Avant is a commercial-stage precision medicine and molecular data-generating company that focuses on the development and commercialization of a series of patented, proprietary data-generating assays that may provide important actionable information for physicians and patients, as well as biopharmaceutical companies, in the areas of oncology.

That's their website, the one on OTCmarkets isn't correct.

